Jump to content

louise henaff

Members
  • Content count

    7
  • Joined

  • Last visited

  • Days Won

    1

louise henaff last won the day on October 27 2016

louise henaff had the most liked content!

Community Reputation

1 Neutral

About louise henaff

  • Rank
    Newbie

Personal Information

  • Gender
    Female
  • Location
    paris
  • Country
    France
  1. This article analyses the work plans of 5 european NITAGs between 2011 and 2014 to identify overlapping topics and similar processes. It aims to identify areas of collaboration between these committees - a burning issue at a time of the Global NITAG Network! http://www.sciencedirect.com/science/article/pii/S0264410X16310362 1-s2.0-S0264410X16310362-main.pdf
  2. In September 2016, STIKO, the German NITAG, launched its own app, the first of its kind in the NITAG community. Anyone can download the app, which is compatible with Android or IOS, and access all STIKO’s recommendations. “This innovative digital project aims to strengthen relationships between healthcare workers and STIKO,” explain Ole Wichmann and Judith Koch from Robert Koch Institute. Why an application? STIKO is slightly different from other NITAGs. The committee does not advise the Ministry of Health, but its recommendations are regarded as good medical practice guidelines and help decide if a vaccine will be reimbursed by insurance companies. STIKO recommendations are almost always implemented, but several studies on barriers and enablers to vaccination in Germany showed how important it is to actively engage with physicians. Medical professionals are the key to engaging the population and the main drivers to promote vaccination. For the past few years, STIKO has been evaluating opportunities to improve communication with private physicians (where the majority of vaccinations are implemented), and the increasing number of them using tablets and smartphones in their daily work life encouraged us to develop an app. How did you develop it? We published a call for tender and the publisher Börm Bruckmeyer, who has experience in developing medical apps, convinced us. Three people from the immunization unit at the Robert Koch Institute got involved, and we also appealed to the IT department to help with the algorithm. Altogether, the whole process took about a year, from design to launch. What can be found in this app? All recommendations issued by STIKO, and published annually in the Epidemiological bulletin of the Robert Koch Institute, are fully reproduced. Instruction leaflets for all vaccines and FAQs for vaccination are also available on the app’s home screen, as well as up-to-date information on supply bottlenecks or new STIKO recommendations and opinion papers. Why would a NITAG want to communicate its recommendations? The stakes are high when promoting our recommendations to all healthcare workers. Well informed physicians will be better equipped to talk to their patients and so improve the acceptance of vaccination, which will in turn increase vaccination rates. source:http://www.nitag-resource.org/news-and-events/news/95-digital-communication-for-nitags-is-no-longer-optional
  3. STIKO (The NITAG of Germany) recommends to use either the nasal vaccine ( LAIV) or an inactivated vaccine (IIA) in the coming season 2016/2017 for children aged from 2-17 years. 39_16_STIKO-Stellungnahme.pdf
  4. JCVI meeting

    The 3rd JCVI meeting will be held on October 5th, 2016 in London. The representatives of Albanian NITAG will attend JCVI meeting and meet with JCVI Secretariat. The agenda will be published nearer the time on the JCVI page, accessible here
  5. WHO China Office and China Preventive Medicine Association (CPMA) are co-hosting an international workshop on new vaccine introduction through a strong NITAG in China. This workshop will support China’s EPI system to strengthen its NITAG and its evidence-based recommendations for the introduction of new vaccines. The International workshop will be held on 21 September 2016 in Beijing, China. The objectives of the workshop are to: (1) Share knowledge and best practices for new vaccine introduction and NITAG strengthening from global, regional, and national perspectives; (2) Make recommendations to improve the ability of China’s EPI system to add new vaccines to the program through a strong NITAG. Both the JCVI and STIKO (the German NITAG) are invited and will present on an aspect of the new vaccine introduction / recommendation processes in the UK and in Germany. Their participations to discussion pannels will also contribute to support China’s EPI system to strengthen its NITAG and its evidence-based recommendations for the introduction of new vaccines.
  6. Background Target groups for seasonal influenza vaccination are defined at the country level and are based on several factors. However, little is known about the national decision-making procedures. Objective The purpose of this study was to compare the evidence used for the development of recommendations and its impact on the choice of target groups in France and the Netherlands. Methods A preliminary documentary analysis identified institutions to include in the assessment: governmental authorities, research institutions, associations, and manufacturers. At least one expert from each group was invited to our study. Thirty-three semi-structured interviews were conducted in 2013 (16 France, 17 the Netherlands). We used NVivo10® to perform a thematic content analysis. Results Clinical/epidemiological studies were the evidence most used in both countries. Economic models were increasingly being used; these had greater influence on the decision making in the Netherlands than in France, probably because of the presence of a modeler. Generally, the quality of the evidence used was poor, although no systematic use of standard protocol for its assessment was observed. A general protocol was sometimes used in France; however, the personal judgment of the experts was crucial for the assessment in both countries. Conclusions There were differences in the target groups, for example, pregnant women, recommended only in France. France and the Netherlands use similar evidence for developing vaccination recommendations, although different decisions are sometimes made regarding target groups. This could be associated with the lack of systematic standard appraisals, increasing the influence of the experts’ judgment on decision making. The development of standards for the appraisal of evidence is recommended. 27ea6eccb2d10e19e10f6b600ce1d7b95e900a2b.pdf
  7. In August 2016, JCVI was asked to review updated data from the 2015/16 season in the UK and other countries, in light of emerging evidence of low effectiveness of the nasal spray vaccine, lower than inactivated vaccine, reported in the United States (US). After reviewing evidence from across the UK, Finland, Canada and the United States following the 2015/16 influenza season, much of which demonstrates good overall effectiveness, JCVI continues to recommend using the live attenuated influenza vaccine (LAIV, the nasal spray vaccine) for preventing flu in children and strongly supports the continuation of the UK childhood influenza immunisation programme. af941e3b2d3cfb85d626b281fc3d8daf4775ac85.pdf
×